BioMarin Announces Positive Phase 3 Pivotal Study Results for VOXZOGO® in Children with Hypochondroplasia
BioMarin Presents New Data on the Effect of Long-Term Treatment with VOXZOGO® on Arm Span, Bone Health and Growth in Children With Achondroplasia at the Pediatric Endocrine Society's 2026 Annual Meeting
BioMarin to Host First Quarter 2026 Financial Results Conference Call and Webcast on Monday, May 4, 2026, at 4:30pm ET
BioMarin Presents New Data on the Positive Impact of Early Treatment With VOXZOGO® on Proportionality and Arm Span in Children with Achondroplasia at the 2026 American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting
U.S. Food and Drug Administration Approves BioMarin's PALYNZIQ® for Adolescents 12 Years of Age and Older with Phenylketonuria
BioMarin to Host Fourth Quarter and Full-Year 2025 Financial Results Conference Call and Webcast on Monday, February 23, 2026, at 4:30pm ET
BioMarin to Host Fourth Quarter and Full-Year 2025 Financial Results Conference Call and Webcast on Monday, February 23, 2026, at 4:30pm ET
BioMarin to Host Fourth Quarter and Full-Year 2025 Financial Results Conference Call and Webcast on Monday, February 23, 2026, at 4:30pm ET
Blue Jay Gold Corp. Announces Engagement of Oak Hill Financial Inc. for Investor Relations and Retention of Haywood Securities for Market Making Services
QIMC Highlights Technical Advisory Role on First Atlas Matane Natural Hydrogen Project Following Quebec Parliamentary Committee Appearance
